Baxalta | search
Click here to view Baxalta news from 60+ newspapers.
Bookmark or Share- Shire cans Baxalta hemophilia B gene therapy, thinning field for ...Shire ($SHPG) has scrapped plans to further develop BAX 335, a hemophilia B gene therapy it gained in its $32 billion takeover of Baxalta.
- UPDATED: Shire finally gets it done, bagging Baxalta in $32B buyoutShire is paying $18 a share plus stock to bag Baxalta in a pact that is worth a total of $45.57 for a share of Baxalta. The deal arrives right on schedule, in a manner of speaking, giving Shire...
- Shire, Baxalta Complete $32B Merger - genengnews.comShire said today it has completed its $32 billion merger with Baxalta, creating what it called the global market leader in rare diseases and other specialized disorders.
- Shire completes combination with Baxalta creating the global ... - TakedaDublin, Ireland – June 3, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) today completed its previously announced combination with Baxalta Incorporated (NYSE: BXLT), creating the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions.
- Baxalta: Examining the Product and Manufacturing Positions of the New ...Baxalta, the newly spun-off company from Baxter Healthcare, has launched as a new separate, independent $6 billion biopharmaceutical company. So what are the product and manufacturing positions of the new company and the executive team that will lead the new company?
More
